HEADER APOPTOSIS 08-FEB-23 8G3X TITLE MBP-MCL1 IN COMPLEX WITH LIGAND 32 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MALTODEXTRIN-BINDING PROTEIN, INDUCED MYELOID LEUKEMIA CELL COMPND 3 DIFFERENTIATION PROTEIN MCL-1 CHIMERA; COMPND 4 CHAIN: A; COMPND 5 SYNONYM: BCL-2-LIKE PROTEIN 3,BCL2-L-3,BCL-2-RELATED PROTEIN COMPND 6 EAT/MCL1,MCL1/EAT; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SERRATIA SP. FS14, HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 1327989, 9606; SOURCE 5 STRAIN: FS14; SOURCE 6 GENE: MALE, JW3994, MCL1, BCL2L3; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS MYELOID CELL LEUKEMIA 1, MCL-1, B-CELL LYMPHOMA 2, BCL-2, BH3 KEYWDS 2 MIMETIC, PROTEIN-PROTEIN INTERACTION, MODULATOR, APOPTOSIS, CANCER, KEYWDS 3 LEUKEMIA, MYELOMA, LYMPHOMA, PHYSICOCHEMICAL PROPERTIES, ADME KEYWDS 4 PROPERTIES, CARDIOTOXICITY, THERAPEUTIC WINDOW EXPDTA X-RAY DIFFRACTION AUTHOR B.R.MILLER,P.SHAFFER REVDAT 2 24-MAY-23 8G3X 1 JRNL REVDAT 1 17-MAY-23 8G3X 0 JRNL AUTH F.ROMANOV-MICHAILIDIS,C.C.HSIAO,L.M.URNER,S.JERHAOUI, JRNL AUTH 2 M.SURKYN,B.MILLER,A.VOS,M.DOMINGUEZ BLANCO,R.BUETERS, JRNL AUTH 3 P.VINKEN,M.BEKKERS,D.WALKER,B.PIETRAK,W.EYCKMANS, JRNL AUTH 4 J.L.DORES-SOUSA,S.JOO KOO,W.LENTO,M.BAUSER,U.PHILIPPAR, JRNL AUTH 5 F.J.R.ROMBOUTS JRNL TITL DISCOVERY OF AN ORAL, BEYOND-RULE-OF-FIVE MCL-1 JRNL TITL 2 PROTEIN-PROTEIN INTERACTION MODULATOR WITH THE POTENTIAL OF JRNL TITL 3 TREATING HEMATOLOGICAL MALIGNANCIES. JRNL REF J.MED.CHEM. V. 66 6122 2023 JRNL REFN ISSN 0022-2623 JRNL PMID 37114951 JRNL DOI 10.1021/ACS.JMEDCHEM.2C01953 REMARK 2 REMARK 2 RESOLUTION. 1.46 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 7.1.015 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.46 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 80.53 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 87951 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.184 REMARK 3 R VALUE (WORKING SET) : 0.182 REMARK 3 FREE R VALUE : 0.206 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT : 4829 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4042 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 127 REMARK 3 SOLVENT ATOMS : 557 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 34.34 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.06000 REMARK 3 B22 (A**2) : -1.55000 REMARK 3 B33 (A**2) : 0.49000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.073 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.072 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.064 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.807 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 8G3X COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-FEB-23. REMARK 100 THE DEPOSITION ID IS D_1000272041. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-SEP-21 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X10SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER2 X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC 1.1.7 REMARK 200 DATA SCALING SOFTWARE : AIMLESS 0.7.7 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 92781 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.460 REMARK 200 RESOLUTION RANGE LOW (A) : 80.530 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 200 DATA REDUNDANCY : 8.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.05400 REMARK 200 FOR THE DATA SET : 16.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.46 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.48 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.3 REMARK 200 DATA REDUNDANCY IN SHELL : 8.50 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 1.22600 REMARK 200 FOR SHELL : 1.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER 7.1.015 REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.49 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.25 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20.5% (W/V) PEG3350, 0.11M MG FORMATE, REMARK 280 PH 7.5, VAPOR DIFFUSION, TEMPERATURE 285K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 49.70000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 68.68900 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 49.70000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 68.68900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, R REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU A -193 CD OE1 OE2 REMARK 480 LYS A -162 NZ REMARK 480 LYS A -94 NZ REMARK 480 LYS A -69 NZ REMARK 480 LYS A -59 CE NZ REMARK 480 LYS A -26 NZ REMARK 480 LYS A -21 CD CE NZ REMARK 480 LYS A -17 CD CE NZ REMARK 480 LYS A 6 CE NZ REMARK 480 GLN A 129 CD OE1 NE2 REMARK 480 LYS A 234 CE NZ REMARK 480 GLU A 240 CD OE1 OE2 REMARK 480 LYS A 244 CE NZ REMARK 480 ARG A 248 CD NE CZ NH1 NH2 REMARK 480 LYS A 308 CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A -28 -74.77 -82.02 REMARK 500 TYR A 87 -56.29 -120.77 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A1157 DISTANCE = 6.53 ANGSTROMS DBREF1 8G3X A -196 170 UNP A0A4P1LXE0_SERSF DBREF2 8G3X A A0A4P1LXE0 2 368 DBREF 8G3X A 173 321 UNP Q07820 MCL1_HUMAN 173 321 SEQADV 8G3X GLY A 171 UNP A0A4P1LXE LINKER SEQADV 8G3X SER A 172 UNP A0A4P1LXE LINKER SEQADV 8G3X ALA A 194 UNP Q07820 LYS 194 CONFLICT SEQADV 8G3X ALA A 197 UNP Q07820 LYS 197 CONFLICT SEQADV 8G3X ALA A 201 UNP Q07820 ARG 201 CONFLICT SEQRES 1 A 518 GLY LYS ILE GLU GLU GLY LYS LEU VAL ILE TRP ILE ASN SEQRES 2 A 518 GLY ASP LYS GLY TYR ASN GLY LEU ALA GLU VAL GLY LYS SEQRES 3 A 518 LYS PHE GLU LYS ASP THR GLY ILE LYS VAL THR VAL GLU SEQRES 4 A 518 HIS PRO ASP LYS LEU GLU GLU LYS PHE PRO GLN VAL ALA SEQRES 5 A 518 ALA THR GLY ASP GLY PRO ASP ILE ILE PHE TRP ALA HIS SEQRES 6 A 518 ASP ARG PHE GLY GLY TYR ALA GLN SER GLY LEU LEU ALA SEQRES 7 A 518 GLU ILE THR PRO ASP LYS ALA PHE GLN ASP LYS LEU TYR SEQRES 8 A 518 PRO PHE THR TRP ASP ALA VAL ARG TYR ASN GLY LYS LEU SEQRES 9 A 518 ILE ALA TYR PRO ILE ALA VAL GLU ALA LEU SER LEU ILE SEQRES 10 A 518 TYR ASN LYS ASP LEU LEU PRO ASN PRO PRO LYS THR TRP SEQRES 11 A 518 GLU GLU ILE PRO ALA LEU ASP LYS GLU LEU LYS ALA LYS SEQRES 12 A 518 GLY LYS SER ALA LEU MET PHE ASN LEU GLN GLU PRO TYR SEQRES 13 A 518 PHE THR TRP PRO LEU ILE ALA ALA ASP GLY GLY TYR ALA SEQRES 14 A 518 PHE LYS TYR GLU ASN GLY LYS TYR ASP ILE LYS ASP VAL SEQRES 15 A 518 GLY VAL ASP ASN ALA GLY ALA LYS ALA GLY LEU THR PHE SEQRES 16 A 518 LEU VAL ASP LEU ILE LYS ASN LYS HIS MET ASN ALA ASP SEQRES 17 A 518 THR ASP TYR SER ILE ALA GLU ALA ALA PHE ASN LYS GLY SEQRES 18 A 518 GLU THR ALA MET THR ILE ASN GLY PRO TRP ALA TRP SER SEQRES 19 A 518 ASN ILE ASP THR SER LYS VAL ASN TYR GLY VAL THR VAL SEQRES 20 A 518 LEU PRO THR PHE LYS GLY GLN PRO SER LYS PRO PHE VAL SEQRES 21 A 518 GLY VAL LEU SER ALA GLY ILE ASN ALA ALA SER PRO ASN SEQRES 22 A 518 LYS GLU LEU ALA LYS GLU PHE LEU GLU ASN TYR LEU LEU SEQRES 23 A 518 THR ASP GLU GLY LEU GLU ALA VAL ASN LYS ASP LYS PRO SEQRES 24 A 518 LEU GLY ALA VAL ALA LEU LYS SER TYR GLU GLU GLU LEU SEQRES 25 A 518 ALA LYS ASP PRO ARG ILE ALA ALA THR MET GLU ASN ALA SEQRES 26 A 518 GLN LYS GLY GLU ILE MET PRO ASN ILE PRO GLN MET SER SEQRES 27 A 518 ALA PHE TRP TYR ALA VAL ARG THR ALA VAL ILE ASN ALA SEQRES 28 A 518 ALA SER GLY ARG GLN THR VAL ASP GLU ALA LEU LYS ASP SEQRES 29 A 518 ALA GLN THR GLY SER GLU LEU TYR ARG GLN SER LEU GLU SEQRES 30 A 518 ILE ILE SER ARG TYR LEU ARG GLU GLN ALA THR GLY ALA SEQRES 31 A 518 ALA ASP THR ALA PRO MET GLY ALA SER GLY ALA THR SER SEQRES 32 A 518 ARG LYS ALA LEU GLU THR LEU ARG ARG VAL GLY ASP GLY SEQRES 33 A 518 VAL GLN ARG ASN HIS GLU THR ALA PHE GLN GLY MET LEU SEQRES 34 A 518 ARG LYS LEU ASP ILE LYS ASN GLU ASP ASP VAL LYS SER SEQRES 35 A 518 LEU SER ARG VAL MET ILE HIS VAL PHE SER ASP GLY VAL SEQRES 36 A 518 THR ASN TRP GLY ARG ILE VAL THR LEU ILE SER PHE GLY SEQRES 37 A 518 ALA PHE VAL ALA LYS HIS LEU LYS THR ILE ASN GLN GLU SEQRES 38 A 518 SER CYS ILE GLU PRO LEU ALA GLU SER ILE THR ASP VAL SEQRES 39 A 518 LEU VAL ARG THR LYS ARG ASP TRP LEU VAL LYS GLN ARG SEQRES 40 A 518 GLY TRP ASP GLY PHE VAL GLU PHE PHE HIS VAL HET GLC R 1 12 HET GLC R 2 11 HET EDO A 501 4 HET EDO A 502 4 HET EDO A 503 4 HET EDO A 504 4 HET EDO A 505 4 HET EDO A 506 4 HET EDO A 507 4 HET EDO A 508 4 HET EDO A 509 4 HET EDO A 510 4 HET YLF A 511 64 HETNAM GLC ALPHA-D-GLUCOPYRANOSE HETNAM EDO 1,2-ETHANEDIOL HETNAM YLF N-[(1'S,3AS,5R,15S,17S,19Z,21R,21AR)-6'-CHLORO-20- HETNAM 2 YLF FLUORO-21-{[(5S,9AS)-HEXAHYDROPYRAZINO[2,1-C][1, HETNAM 3 YLF 4]OXAZIN-8(1H)-YL]METHYL}-21-METHOXY-17-METHYL-13,15- HETNAM 4 YLF DIOXO-2,3,3',3A,4,4',13,16,17,18,21,21A-DODECAHYDRO- HETNAM 5 YLF 2'H,6H,8H-15LAMBDA~6~-SPIRO[10,12-(ETHANEDIYLIDENE)- HETNAM 6 YLF 15LAMBDA~6~-FURO[3,2-I][1,4]OXAZEPINO[3,4-F][1,2, HETNAM 7 YLF 7]THIADIAZACYCLOHEXADECINE-7,1'-NAPHTHALEN]-15-YL]-3- HETNAM 8 YLF METHOXY-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE HETSYN GLC ALPHA-D-GLUCOSE; D-GLUCOSE; GLUCOSE HETSYN EDO ETHYLENE GLYCOL FORMUL 2 GLC 2(C6 H12 O6) FORMUL 3 EDO 10(C2 H6 O2) FORMUL 13 YLF C46 H59 CL F N7 O8 S FORMUL 14 HOH *557(H2 O) HELIX 1 AA1 GLY A -180 GLY A -164 1 17 HELIX 2 AA2 LYS A -154 THR A -143 1 12 HELIX 3 AA3 ARG A -130 SER A -123 1 8 HELIX 4 AA4 ASP A -114 ASP A -109 1 6 HELIX 5 AA5 TYR A -106 VAL A -99 1 8 HELIX 6 AA6 GLU A -65 ALA A -55 1 11 HELIX 7 AA7 GLU A -43 ASP A -32 1 12 HELIX 8 AA8 ASN A -11 ASN A 5 1 17 HELIX 9 AA9 ASP A 13 LYS A 23 1 11 HELIX 10 AB1 GLY A 32 TRP A 34 5 3 HELIX 11 AB2 ALA A 35 LYS A 43 1 9 HELIX 12 AB3 ASN A 76 TYR A 87 1 12 HELIX 13 AB4 THR A 90 LYS A 101 1 12 HELIX 14 AB5 LEU A 108 ALA A 116 1 9 HELIX 15 AB6 ASP A 118 GLY A 131 1 14 HELIX 16 AB7 GLN A 139 GLY A 157 1 19 HELIX 17 AB8 THR A 160 GLY A 192 1 33 HELIX 18 AB9 SER A 202 HIS A 224 1 23 HELIX 19 AC1 HIS A 224 ASP A 236 1 13 HELIX 20 AC2 ASN A 239 SER A 245 1 7 HELIX 21 AC3 SER A 245 PHE A 254 1 10 HELIX 22 AC4 ASN A 260 ILE A 281 1 22 HELIX 23 AC5 GLN A 283 SER A 285 5 3 HELIX 24 AC6 CYS A 286 GLN A 309 1 24 HELIX 25 AC7 ARG A 310 PHE A 319 1 10 SHEET 1 AA1 6 VAL A-161 GLU A-158 0 SHEET 2 AA1 6 LEU A-189 TRP A-186 1 N ILE A-187 O GLU A-158 SHEET 3 AA1 6 ILE A-137 ALA A-133 1 O PHE A-135 N TRP A-186 SHEET 4 AA1 6 PHE A 62 ILE A 70 -1 O GLY A 69 N ILE A-136 SHEET 5 AA1 6 TYR A -90 GLU A -85 -1 N ILE A -88 O LEU A 66 SHEET 6 AA1 6 ALA A 105 VAL A 106 -1 O ALA A 105 N VAL A -86 SHEET 1 AA2 5 VAL A-161 GLU A-158 0 SHEET 2 AA2 5 LEU A-189 TRP A-186 1 N ILE A-187 O GLU A-158 SHEET 3 AA2 5 ILE A-137 ALA A-133 1 O PHE A-135 N TRP A-186 SHEET 4 AA2 5 PHE A 62 ILE A 70 -1 O GLY A 69 N ILE A-136 SHEET 5 AA2 5 GLU A 132 ILE A 133 1 O GLU A 132 N VAL A 63 SHEET 1 AA3 2 ARG A -98 TYR A -97 0 SHEET 2 AA3 2 LYS A -94 LEU A -93 -1 O LYS A -94 N TYR A -97 SHEET 1 AA4 4 SER A -51 LEU A -49 0 SHEET 2 AA4 4 THR A 26 ASN A 31 1 O ALA A 27 N SER A -51 SHEET 3 AA4 4 SER A -82 ASN A -78 -1 N ASN A -78 O ALA A 27 SHEET 4 AA4 4 TYR A 46 THR A 49 -1 O THR A 49 N LEU A -81 SHEET 1 AA5 2 TYR A -29 GLU A -24 0 SHEET 2 AA5 2 LYS A -21 GLY A -14 -1 O ASP A -19 N LYS A -26 LINK O4 GLC R 1 C1 GLC R 2 1555 1555 1.41 CRYST1 99.400 137.378 38.491 90.00 90.00 90.00 P 21 21 2 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010060 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007279 0.000000 0.00000 SCALE3 0.000000 0.000000 0.025980 0.00000